ARC Clinical Research is enrolling women ages 16-40 in a study that could help eradicate one of the most infectious causes of birth defects in the world, cytomegalovirus (CMV).
How cytomegalovirus affects women and children
CMV is a common viral infection that usually goes unnoticed or only causes mild symptoms in most people. But if a woman becomes infected with CMV while pregnant, she can pass the infection to her unborn baby. This can cause long-term disability due to birth defects, including hearing loss. Currently, there is no approved vaccine against CMV.
Moderna has begun testing a new mRNA vaccine to prevent CMV infections in women of child-bearing age. ARC Clinical Research is participating in the national trials of this vaccine.
Who can participate
- Women between 16-40 years of age
- In good health
- In close contact with at least one child 5 years of age or younger for at least 8 hours a week, if age 20 or older
- Not pregnant or planning on becoming pregnant within the next 9 months
What to expect
The 30-month trial includes in-person visits and phone contact. Participants will be compensated for time and travel.
How to enroll in the clinical study
ARC Clinical Research looks at new ways to prevent, detect, or treat diseases that affect our community. Volunteers in research studies — people just like you — are a critical link in making these discoveries possible.
Learn more about the cytomegalovirus vaccine study. Call 512-225-5931 to enroll.